Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

A 10-year restrospective evaluation of ultrasound in pregnant abdominal trauma patients.

Meisinger QC, Brown MA, Dehqanzada ZA, Doucet J, Coimbra R, Casola G.

Emerg Radiol. 2016 Apr;23(2):105-9. doi: 10.1007/s10140-015-1367-9. Epub 2015 Nov 19.

PMID:
26585759
2.

Complete ultrasonography of trauma in screening blunt abdominal trauma patients is equivalent to computed tomographic scanning while reducing radiation exposure and cost.

Dehqanzada ZA, Meisinger Q, Doucet J, Smith A, Casola G, Coimbra R.

J Trauma Acute Care Surg. 2015 Aug;79(2):199-205. doi: 10.1097/TA.0000000000000715.

PMID:
26218686
3.

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S.

Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448.

4.

Epithelioid angiosarcoma of the aorta in a 47-year-old man: a case report and literature review.

Dehqanzada ZA, Menezes G, Mukherjee D.

J Surg Educ. 2007 May-Jun;64(3):165-70.

PMID:
17574179
5.

Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients.

Hamsher C, Smith AM, Dehqanzada ZA, Khoo S, Ponniah S, Peoples GE, Moroni M.

Cancer Immunol Immunother. 2007 Nov;56(11):1711-21. Epub 2007 Apr 18.

PMID:
17440722
6.

Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.

Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE.

Oncol Rep. 2007 Mar;17(3):687-94.

PMID:
17273752
7.

Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.

Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE.

Cancer Immunol Immunother. 2007 Feb;56(2):135-46. Epub 2006 Jun 17.

PMID:
16783576
8.

Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.

Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE.

Clin Cancer Res. 2006 Jan 15;12(2):478-86.

9.

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.

Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE.

Clin Cancer Res. 2005 Oct 15;11(20):7470-9.

10.

Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.

Van Rompay KK, Marthas ML, Lifson JD, Berardi CJ, Vasquez GM, Agatep E, Dehqanzada ZA, Cundy KC, Bischofberger N, Pedersen NC.

AIDS Res Hum Retroviruses. 1998 Jun 10;14(9):761-73.

PMID:
9643376

Supplemental Content

Loading ...
Support Center